Global Hashimoto's Thyroiditis Market Research and Forecast 2022-2028

Description

List of Tables

Global Hashimoto's Thyroiditis Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Thyroid-Stimulating Hormone Test, Thyroxine Test, Antithyroid Antibody Test), By Treatment (Levothyroxine, Triiodothyronine, Desiccated Thyroid Extract and other), Distribution Channel (Hospital Pharmacies, and Retail Pharmacies) Forecast Period 2021-2027

Global Hashimoto's thyroiditis market is anticipated to grow at a considerable CAGR during the forecast period. Hashimoto's thyroiditis is a condition in which the immune system attacks the thyroid and gradually leads to hyperthyroidism. Production of immune cells and autoantibodies by the body's immune system are characteristics of Hashimoto's thyroiditis, which can damage thyroid cells and compromise their ability to make thyroid hormones. There are various treatment methods for such diseases by using replacement agents such as levothyroxine, triiodothyronine, or desiccated thyroid extract. The increasing autoimmune thyroid diseases and deficiency of iodine are responsible for the growth in the demand for Hashimoto's Thyroiditis treatment. Furthermore, there are various national health programs related to thyroid disease that raise awareness regarding such diseases that further fuel the growth of Hashimoto's thyroiditis market.

However, there are stringent regulations of food and drug administration regarding medication of Hashimoto's Thyroiditis which acts as an obstacle for the market. Although, further research and development for Hashimoto's diseases and the cost-effectiveness of the treatment will turn out to be a huge opportunity for the adoption of Hashimoto's thyroiditis treatment.

Segmental Outlook

The global Hashimoto's thyroiditis market is segmented based on diagnosis, treatment, and distribution channels. In diagnosis, the market is segmented into Thyroid-stimulating hormone tests, thyroxine tests, antithyroid antibody tests. Moreover, based on treatment, the market is segmented into levothyroxine, triiodothyronine, desiccated thyroid extract, and others. By distribution channel, the treatment market is segmented into hospital pharmacies and retail pharmacies.

Levothyroxine is a major treatment and is considered to dominate the market

Levothyroxine is the first line of treatment for Hashimoto's thyroiditis and will be the dominating segment during the forecast period. Levothyroxine is a hormone medicine treatment for the underactive thyroid gland, the following medicine helps in replacing the missing thyroid hormone. The drug is available in the brand name such as Synthroid, Levoxyl, and Unithroid which are available as oral tablets, oral capsules, or injectable solutions. The medicine is a prescription drug and is used in form of combination therapy. Levothyroxine might be taken life-long while treating hypothyroidism unless the disease becomes transient.

Regional Outlooks

The global Hashimoto's thyroiditis market is further segmented based on geography into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to have a significant market during the forecast period attributed to factors such as the large presence of healthcare facilities in the region, high awareness among the people about the diseases, strategic collaborations between the pharmaceutical companies and government organizations. As per ClinCalc LLC, Levothyroxine was the second most prescribed drug in the US in 2018, a rank higher than a year ago. Around 105 million prescriptions of Levothyroxine were registered in 2018 in the US. AbbVie Inc. is a major manufacturer of Levothyroxine as Synthroid. The company generated a revenue of $770-$780 million each year in the period 2018-2020 from the sale of Levothyroxine as Synthroid in the US.

Asia-Pacific will have significant growth in the global Hashimoto's Thyroiditis Market

Asia Pacific is expected to register significant growth in Hashimoto's Thyroiditis market. The growth is attributed to rising healthcare infrastructure in emerging economies including China, India, and ASEAN countries, along with that rising insurance payer, development, and expansion of public and private healthcare sectors. Further one of the major reasons for the growth of the market in this region is huge investment is done by global companies in local companies of the region due to the presence of raw materials and labor at cheaper cost. The availability of generics in the region is also a major reason for the rise of the market.

Market Players Outlook

The key players of Hashimoto's thyroiditis market include AbbVie Inc., Pfizer Inc., Merck KGaA, IBSA Institut Biochimique SA, among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers, and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in August 2020, Lannett Company, Inc., launched Cediprof, Inc.'s FDA-approved Levothyroxine Sodium Tablets USP, under the companies interim exclusive supply and distribution agreement in the US.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Penicillin and Streptomycin market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2018404

1. Report Summary

1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
- 3.3.1. AbbVie Inc.
  - 3.3.1.1. Overview
  - 3.3.1.2. Financial Analysis
  - 3.3.1.3. SWOT Analysis
  - 3.3.1.4. Recent Developments
- 3.3.2. Pfizer Inc.
  - 3.3.2.1. Overview
  - 3.3.2.2. Financial Analysis
  - 3.3.2.3. SWOT Analysis
  - 3.3.2.4. Recent Developments
- 3.3.3. Merck KGaA
  - 3.3.3.1. Overview
  - 3.3.3.2. Financial Analysis
  - 3.3.3.3. SWOT Analysis
  - 3.3.3.4. Recent Developments
- 3.3.4. IBSAInstitutBiochimique SA
  - 3.3.4.1. Overview
  - 3.3.4.2. Financial Analysis
  - 3.3.4.3. SWOT Analysis
  - 3.3.4.4. Recent Developments

4. Market Determinants

4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation

5.1. Global Hashimoto's Thyroiditis Diagnosis and Treatment Market by Diagnosis
- 5.1.1. Thyroid-Stimulating Hormone Test
- 5.1.2. Thyroxine Test
- 5.1.3. Antithyroid Antibody Test
5.2. Global Hashimoto's Thyroiditis Diagnosis and Treatment Market by Treatment
- 5.2.1. Levothyroxine
- 5.2.2. Triiodothyronine
- 5.2.3. Desiccated Thyroid Extract
- 5.2.4. Other (Liothyronine, Propylthiouracil)
5.3. Global Hashimoto's Thyroiditis Treatment Market by Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Retail Pharmacies

6. Regional Analysis

6.1. North America
- 6.1.1. United States
- 6.1.2. Canada
6.2. Europe
- 6.2.1. UK
- 6.2.2. Germany
- 6.2.3. Italy
- 6.2.4. Spain
- 6.2.5. France
- 6.2.6. Rest of Europe
6.3. Asia-Pacific
- 6.3.1. China
- 6.3.2. India
- 6.3.3. Japan
- 6.3.4. South Korea
- 6.3.5. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles

7.1. AcellaPharmaceuticals, LLC
7.2. Allergan plc
7.3. Bio-Rad Laboratories, Inc.
7.4. General Electric Co.
7.5. Intas Pharmaceuticals Ltd.
7.6. Jerome Stevens Pharmaceuticals, Inc.
7.7. Lannett Company, Inc.
7.8. Lupin Ltd.
7.9. Mylan NV
7.10. Novartis AG
7.11. RLC Labs
7.12. Taj Pharmaceuticals Ltd.